Margalit Rosenkranz
Pediatric Rheumatology Pittsburgh, PA Medical Doctor
NPI 1598848244 CMS profile 665340
3705 Fifth Avenue, Fl 1, Pittsburgh, PA 15213
General payments
$1,333
Research payments
$1,718
Ownership & investment interest
$0
Research they led as principal investigator
$105,477
Through program year 2019, Margalit Rosenkranz of Pittsburgh, PA is reported in the CMS Open Payments database as having received $1,333 across 2 general payments and $1,718 in research payments paid to them. Separately, studies naming them as principal investigator received $105,477 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 74th percentile of Pediatric Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2019 | General | $1,333 | 2 | |
| 2019 | Research | $1,718 | 4 |
Beside peers
- Margalit Rosenkranz
- Pediatric Rheumatology median
- Middle half of Pediatric Rheumatology
- National median
In program year 2025, general payments to Margalit Rosenkranz were reported at $0. Among 204 Pediatric Rheumatology profiles paid that year, the median was $146 and the middle half received between $95 and $522.
Show as a table
| Year | Margalit Rosenkranz | Pediatric Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,333 | $141 | $61–$1,029 | $163 |
| 2020 | $0 | $113 | $33–$419 | $114 |
| 2021 | $0 | $189 | $61–$1,640 | $132 |
| 2022 | $0 | $120 | $28–$404 | $149 |
| 2023 | $0 | $97 | $41–$222 | $160 |
| 2024 | $0 | $139 | $48–$606 | $164 |
| 2025 | $0 | $146 | $95–$522 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
13
Drug cost
$73,298
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Orencia Clickject Abatacept | Brand | 13 | $73,298 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
6 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Rheumatology in Pennsylvania
Sarah Bayefsky
Pediatric Rheumatology · Philadelphia, PA
Edward Behrens
Pediatric Rheumatology · Philadelphia, PA
Pamela Weiss
Pediatric Rheumatology · Philadelphia, PA
Kathryn Torok
Pediatric Rheumatology · Pittsburgh, PA
Karen James
Pediatric Rheumatology · Philadelphia, PA
Scott Canna
Pediatric Rheumatology · Pittsburgh, PA
Related records
Pediatric Rheumatology in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.